Literature DB >> 1996046

Urinary tract infection: economic considerations.

J P Patton1, D B Nash, E Abrutyn.   

Abstract

Urinary tract infection results in significant morbidity and mortality while consuming large amounts of national resources. The prevention, diagnosis, and treatment of urinary tract infection produce both costs and benefits, and economic analysis provides a rational framework for looking at these effects. The goals and methods of economic analysis in medicine are summarized, and strategies to address uncomplicated cystitis, nosocomial urinary tract infection, and pyelonephritis are reviewed, with an emphasis on the economic trade-offs faced by decision makers.

Entities:  

Mesh:

Year:  1991        PMID: 1996046     DOI: 10.1016/s0025-7125(16)30466-7

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  38 in total

1.  Management of uncomplicated urinary tract infections.

Authors:  Timothy Jancel; Vicky Dudas
Journal:  West J Med       Date:  2002-01

2.  Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.

Authors:  K Thankavel; B Madison; T Ikeda; R Malaviya; A H Shah; P M Arumugam; S N Abraham
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration.

Authors:  M LeBrun; L Grenier; P Gourde; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Pharmacologic Basis for the Treatment of Pyelonephritis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

5.  Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract.

Authors:  N M Graham
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 6.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 7.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

8.  Improved repetitive-element PCR fingerprinting for resolving pathogenic and nonpathogenic phylogenetic groups within Escherichia coli.

Authors:  J R Johnson; T T O'Bryan
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

9.  Managing urinary tract infections in nursing homes: a qualitative assessment.

Authors:  Anna K Schweizer; Carmel M Hughes; Domhnall C Macauley; Ciaran O'Neill
Journal:  Pharm World Sci       Date:  2005-06

10.  Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women.

Authors:  T C M Christiaens; M De Meyere; G Verschraegen; W Peersman; S Heytens; J M De Maeseneer
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.